Daewoong Pharmaceutical's Nabota to Expand Middle East Market...Kuwait Signs Export Agreement
Jul 27, 2025
|
Daewoong Pharmaceutical said it recently signed a contract to export Kuwait, the fifth Middle Eastern country. It is the fourth advancement after the UAE, Saudi Arabia, and Qatar in the six Gulf Coast countries, which are considered the premium markets representing the Middle East due to their high interest in beauty and plastic surgery.
Kuwait has a high per capita income (about $32,000), a well-equipped medical infrastructure, and active exchanges with other Gulf Coast countries are expected to create synergy. Daewoong Pharmaceutical will use Kuwait as a bridgehead to expand its entry into Nabota throughout the Gulf Coast countries.
Daewoong Pharmaceutical is currently stepping up its efforts to enter the Middle East market by entering botulinum toxin preparations in the largest number of domestic toxin brands. In particular, Daewoong Pharmaceutical is creating a 'WIN-WIN-WIN' model that can satisfy not only the company but also the medical staff and patients by increasing the treatment capacity of Middle East medical staff and increasing the treatment satisfaction and service quality experienced by patients.
Yoon Jun-su, head of Nabota Business Division at Daewoong Pharmaceutical, said, "This entry into Kuwait will contribute to strengthening Nabota's entry into the premium toxin market in the Middle East by establishing itself as a brand representing the premium toxin market in the Middle East. We will quickly expand our presence throughout the Middle East through differentiated academic activities and dissemination of independent procedures based on clinical evidence and data." he said.
This article was translated by Naver AI translator.
